Clinical Trial for Advanced Non-Small Cell Lung Cancer
This study is for people with advanced non-small cell lung cancer (NSCLC Stage IV) whose cancer has become resistant to previous immunotherapy. It's testing if a combination of N-803, tislelizumab, and docetaxel, or a previously failed immunotherapy with docetaxel, works better than docetaxel alone. Researchers will compare how long people live (Overall Survival) over approximately 12 months. You might be eligible if you are 18 to 90 years old and have stage IV NSCLC. The study is looking for 507 participants.
- Study design
- This is a randomized, open-label study with two groups, comparing different drug combinations to docetaxel alone. Participants will be randomly assigned to a treatment group.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, Overall Survival, will be measured at approximately 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06745908
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Recruiting
PHASE3Ages 18–90InterventionalTreatmentImmunityBio, Inc.
~507 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:N-803TislelizumabDocetaxelPrior failed checkpoint inhibitor
At a glance
Recruiting sites
34 of 36 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Compare Overall Survival between the experimental and control arms
Measured over Approximately 12 months
Conditions
Where it's being run
36 sites across 24 statesOntario5
California4
Florida3
Ohio2
Tennessee2
Virginia2
Arkansas1
Georgia1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Compare Overall Survival between the experimental and control armsApproximately 12 months